GNOS-PV02
- Generic Name
- GNOS-PV02
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC
Phase 1
Active, not recruiting
- Conditions
- HCC
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Geneos Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT04251117
- Locations
- 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇳🇿Auckland Clinical Studies, Auckland, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath